1391926-35-4

Basic information

• Product Name: 4-(4-(benzylsulfonyl)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine
• Synonyms: 4-(4-(benzylsulfonyl)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine
• CAS NO: 1391926-35-4
• Molecular Weight: 520.612
• Mol File: 1391926-35-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(4-(benzylsulfonyl)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(benzylsulfonyl)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine(1391926-35-4)
• EPA Substance Registry System: 4-(4-(benzylsulfonyl)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine(1391926-35-4)

Safety Data

• Hazardous Substances Data: 1391926-35-4(Hazardous Substances Data)

Upstream product

• 25713-57-9 2-benzylsulfanyl-4,6-dichloro-[1,3,5]triazine 
• 1266386-31-5 4-bromo-2-(tetrahydro-2H-pyran-2-yl)-2H-indazole 
• 110-87-2 3,4-dihydro-2H-pyran 
• 186407-74-9 4-bromoindazole 
• 1391926-34-3 4-(4-(benzylthio)-6-(2-(tetrahydro-2H-pyran-2-yl)-2H-indazol-4-yl)-1,3,5-triazin-2-yl)morpholine 
• 41748-71-4 4-aminoindazole 
• 603-83-8 3-nitro-o-tolylamine 
• 885618-33-7 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 2942-40-7 nitro-4 indazole 

Downstream Products

• 1391926-36-5 C₂₈H₃₁N₇O₄ 
• 1391925-55-5 3-((4-(1H-indazol-4-yl)-6-morpholino-1,3,5-triazin-2-yl)amino)-N,N-dimethylbenzamide 
• 1542268-07-4 C₂₈H₃₇N₇O₄ 
• 1542268-06-3 (1r,4r)-4-((4-(2H-indazol-4-yl)-6-morpholino-1,3,5-triazine-2-yl)oxy)-N,N-dimethycyclohexanecarboxamide hydrochloride 

Relevant articles and documents

Discovery of Novel and Orally Bioavailable Inhibitors of PI3 Kinase Based on Indazole Substituted Morpholino-Triazines

A new class of potent PI3Kα inhibitors is identified based on aryl substituted morpholino-triazine scaffold. The identified compounds showed not only a high level of enzymatic and cellular potency in nanomolar range but also high oral bioavailability. The three lead molecules (based on their in vitro potency) when evaluated further for in vitro metabolic stability as well as pharmacokinetic profile led to the identification of 26, as a candidate for further development. The IC50 and EC50 value of 26 is 60 and 500 nM, respectively, for PI3Kα enzyme inhibitory activity and ovarian cancer (A2780) cell line. The identified lead also showed a high level of microsomal stability and minimal inhibition activity for CYP3A4, CYP2C19, and CYP2D6 at 10 μM concentrations. The lead compound 26, demonstrated excellent oral bioavailability with an AUC of 5.2 μM at a dose of 3 mpk in mice and found to be well tolerated in mice when dosed at 30 mpk BID for 5 days.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.